|
|
|
| home > ebr > spring 2003 > signal transduction in breast cancer: silencing the cross-talk |
|
|
 PUBLICATIONS |
European Biopharmaceutical Review
|
| Signal transduction pathways mediate the ability of cells to respond to hormonal and environmental stimuli. Diverse and rapid cellular responses to external stimuli may involve proliferation, differentiation, migration or programmed cell death. In the normal cell a tightly regulated cross-talk network between multiple independent and convergent pathways maintains the cell in a specific developmental and functional pathway. Aberrations in these signal transduction pathways can result in cellular transformation. Furthermore, experimental evidence suggests that pathway cross-talk augments the tumorigenic and metastatic potential of transformed cells. Additionally, cross-talk between diverse signal transduction pathways appears to play a critical role in the progression and therapeutic resistance of breast cancer. |
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
By Dr Frank E Jones, Department of Structural and Cellular Biology, Dr Matthew E Burow, Department of Medicine (Hematology & Medical Oncology), Department of Surgery, and Dr Steven M Hill, Department of Structural and Cellular Biology, at Tulane Cancer Center
Dr Frank E Jones undertook his post-doctoral training at Yale University within the Department of Pathology. He accepted a position as Assistant Professor at Tulane University in the Department of Structural and Cellular Biology in June 2001.
Dr Jones' research interests focus on the development of mouse models to study the molecular mechanisms contributing to metastatic breast, ovarian and prostate cancers.
Dr Matthew E Burow carried out his post-doctoral studies at the Tulane/Xavier Center for Bioenvironmental Research and was subsequently appointed as a Research Assistant Professor in the Department of Pharmacology in 2000. In 2002 Dr Burow accepted his current position as an Assistant Professor in the Section of Hematology and Medical Oncology, Department of Medicine, with an appointment as an Adjunct Assistant Professor in the Department of Surgery. His primary research interests focus on understanding the molecular mechanisms that control oestrogen receptor mediated gene expression and anti-oestrogen resistance in breast carcinoma cells, as well as the way that cell survival and apoptotic signalling pathways regulate the progression of breast carcinoma to a hormone independent and drug resistant phenotype.
Dr Steven M Hill undertook his post-doctoral training at the University of Texas Health Sciences Center, San Antonio, in the Medical Oncology section of the Department of Medicine under the tutelage of the late Dr William L McGuire. Dr Hill joined Tulane University in 1989 as an Assistant Professor and is currently Professor of Structural and Cellular Biology at Tulane University Health Sciences Center and holds the Edmond and Lily Safra Chair for breast cancer research. Dr Hill's general research interests focus on defining the mechanisms of cross-talk between G-protein coupled receptor signalling pathways and steroid hormone receptor signalling pathways in breast cancer. |
|
|
|
|
|
 |
Industry Events |
 |
10th-Anniversary Event RFID Journal LIVE! 2012
3-5 April 2012, Walt Disney World Swan and Dolphin Resort, Orlando, Florida
RFID Journal LIVE! 2012, our tenth annual conference and exhibition, is the only event where you can learn how to use RFID technologies to improve your pharmaceutical and medical packaging business, from real-world case studies across all applications, including asset tracking, logistics and transportation, supply chain management, warehouse and inventory management, security and more. Learn from a customized program featuring more than 50 end-user case studies and 8 industry-specific and how-to conference tracks.
More info >> |
|
 |
News and Press Releases |
 |
Record sales of new de-blistering and leak testing equipment at packaging machinery manufacturer, Sepha Ltd
The packaging machinery manufacturer, Sepha Ltd, has reported record sales of its recently extended range of non-destructive leak testing equipment for the world's pharmaceutical packaging industry. With demand up across all major markets, the company says the increase will fund future R&D and enable it to bring forward future innovations aimed at reducing costs and driving quality for pharmaceutical manufacturers and contract packers.
More info >> |
|
|
